Recent

% | $
Quotes you view appear here for quick access.

ImmunoGen, Inc. Message Board

  • sy3dney sy3dney Feb 22, 2013 1:19 PM Flag

    One surprise in the FDA news

    "The biggest news in today's press release, given that approval was expected, was that the label allows for "The biggest news in today's press release, given that approval was expected, was that the label allows for use in front-line HER-2 positive metastatic breast cancer," says Cowen's Simos Simeonidis in a note.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • "The biggest news in today's press release, given that approval was expected, was that the label allows for use in front-line HER-2 positive metastatic breast cancer," says Cowen's Simos Simeonidis in a note this This morning -- "This was not a major surprise, since EMILIA included about 12% front-line mBC patients (about 60 1st-line mBC patients in the T-DM1 arm of the EMILIA trial), but it was definitely not a given."

 
IMGN
6.11-0.50(-7.56%)May 3 4:00 PMEDT